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Abstract
Unlocking clinically translatable genomic information, including copy number alterations (CNA), from formalin-fixed
paraffin-embedded (FFPE) tissue is challenging due to low yields and degraded DNA. We describe a robust,
cost-effective low-coverage whole genome sequencing (LC WGS) method for CNA detection using 5 ng of
FFPE-derived DNA. CN profiles using 100 ng or 5 ng input DNA were highly concordant and comparable
with molecular inversion probe (MIP) array profiles. LC WGS improved CN profiles of samples that performed
poorly using MIP arrays. Our technique enables identification of driver and prognostic CNAs in archival patient
samples previously deemed unsuitable for genomic analysis due to DNA limitations.
Keywords: Low coverage whole genome sequencing (LC WGS), Low-input DNA, Copy number, Formalin-fixed
paraffin-embedded (FFPE), Next generation sequencing
Background
Identifying the somatic genetic alterations underlying
cancer is critical to our understanding of the disease
drivers and can inform diagnosis, prognosis, and response
to therapy. One of the major genetic alterations in cancer
is copy number alteration (CNA), with aneuploidy and
structural alterations present in most malignancies, as well
as being common in precursor lesions [1]. CNAs reflect
the underlying biology of a tumor [2] and, given suitable
detection methods, could be used in research and poten-
tially in clinical settings to predict patients’ response to
treatment and prognosis. However, the challenge of
obtaining sufficient quantity and quality of DNA from
formalin-fixed paraffin-embedded (FFPE) tissue has se-
verely limited adoption of this approach.
Since the development of comparative genomic
hybridization (CGH) [3], different methods have been
attempted, with varying success, to identify CNAs in
FFPE-derived DNA, including array-CGH and SNP ar-
rays. One of the most reliable approaches available to
date is molecular inversion probe (MIP) technology,
which can obtain high-quality CNA and genotype data
from FFPE samples with less than 100 ng of input DNA
[4]. Additionally, because the MIP assay detects SNPs, it
can also detect allelic imbalance and loss of heterozygos-
ity (LOH) [5]. Whole genome sequencing (WGS) at 30×
coverage can also be used for CNA and LOH detection,
but requires at least 100 ng of high quality input DNA
and has challenges associated with cost, bioinformatics
processing time, and storage of large datasets. CNA from
FFPE-derived DNA using low coverage WGS (LC WGS)
(0.1–2× coverage) has been reported from 100 ng to
1 μg of input DNA [6–9] although point mutations and
LOH were not assayed. Each method has both common
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and unique issues related to the required starting DNA
amount, specificity, sensitivity, genome coverage, and
accuracy as well as cost.
Although the high success rate of CNA by MIP assays
in FFPE-derived DNA makes it arguably the best currently
used method, its application remains limited since in
many research and clinical settings, obtaining 100 ng of
input DNA is often unachievable, particularly for small bi-
opsy samples and pre-cancerous lesions. This limitation is
particularly relevant in an era where neoadjuvant therapies
may be administered before surgery, such that obtaining
sufficient pre-treatment tissue for current CNA tech-
niques from small biopsies is not feasible, once conven-
tional diagnostic assays have been performed. A method
often used to overcome the challenge of a limiting amount
of DNA is whole genome amplification (WGA) to increase
the amount of starting template DNA [9]. However, this
method carries the risk of introducing unintended positive
and/or negative CNA during the amplification process,
potentially causing misinterpretation of the CN profile
[10]. Therefore, there is an urgent need to develop a tech-
nique to detect CNA with high accuracy from very limited
input of FFPE-derived DNA.
The primary goal of this study was to assess the per-
formance of LC WGS to detect CNA using an ultra-low
input of FFPE-derived DNA. We investigated methods
of reducing DNA input and improving performance, in-
cluding WGA, pre-treatment with a DNA repair proced-
ure, and a low-input WGS library preparation method.
The optimal method was then compared to MIP arrays.
Methods
Tumor samples and DNA extraction
Archived FFPE pathology blocks of Merkel cell carcin-
oma (MCC) samples (n = 2) were obtained as previously
described [6]. MCC cells from these previously analyzed
samples were newly micro-dissected by the Roche Auto-
mated Tissue Dissection System (Roche) from 2–3 5-μm
hematoxylin and eosin (H&E) stained sections, followed
by shearing with sonication with the Covaris LE220 sys-
tem. DNA was extracted using a MagAttract® HMW
DNA mini Kit (Qiagen).
FFPE breast tumor samples (n = 4) were obtained for
this study from the LifePool cohort (www.lifepool.org).
LifePool prospectively recruits Australian female partici-
pants through the population-based mammographic
screening program. Participants consent to use of their
diagnostic tissue blocks for research. Ten-micron sec-
tions were H&E stained and DNA was extracted from
manually needle micro-dissected cells using the Qiagen
DNeasy FFPE Kit (Qiagen) as previously described [11]
from both FFPE breast tumor samples and two FFPE
pre-cancerous breast lesions (papilloma). The quality of
DNA was assessed by a multiplex PCR assay [12]
modified to include additional primer sets that produce
up to 700 bp fragments from non-overlapping target
sites in the GAPDH gene.
This study was approved by the Human Research Ethics
Committee at the Peter MacCallum Cancer Centre. This
study was carried out in accordance with all relevant regu-
lations and guidelines.
Whole genome amplification
Extracted DNA from FFPE MCC samples were amplified
using GenomePlex® Complete Whole Genome Amplifica-
tion (WGA) kit (Sigma-Aldrich), following the manufac-
turer’s instruction with several minor modifications. In
brief, 50 ng of DNA was prepared in a total volume of
10 μL for the fragmentation, followed by library prepar-
ation and 14 cycles of amplification as described in the
protocol. The final product was purified using QIAquick®
PCR purification kit (Qiagen), followed by quantification
to determine the final concentration; the yield was 2–4 μg.
The average fragmentation size of WGA products was
200–300 bp. A standard human genomic DNA was used
as a positive control provided with the Genome Plex
WGA kit (Sigma) and a no template control was used as a
negative control.
NEB next FFPE repair
The NEB Next FFPE Repair kit (NEB M6630, New
England® Biolabs Inc) was used for repairing 150 ng
of total DNA, according to the manufacturer’s proto-
col with a minor change of eluting DNA in 30 μL in-
stead of 40 μL. A total of 10 μL of eluted DNA (total
50 ng of repaired DNA) was used for WGA using the
Sigma WGA kit as described above. The remaining
100 ng of repaired DNA was used for the library prep
directly using the KAPA Hyper Prep Kit.
KAPA Hyper library preparation
Library preparation was performed as described in the
KAPA Hyper Prep Kit Illumina® platforms (KR0961-
v1.14, KAPA Bio systems). Slight modifications of the
manufacturer’s protocol were incorporated. Briefly,
100 ng of non-WGA or unamplified DNA (both NEB
Next treated repaired DNA and untreated DNA) was
sheared with sonication (Covaris S2 system) for 3 × 60 s,
with the following parameters: duty cycles of 10, inten-
sity of 5, and 200 cycles/burst.
Subsequently, libraries of the both the fragmented un-
amplified DNA (200–400 bp) and WGA products were
created by end repair and A-tailing, adaptor ligation with
a stock concentration of 15 μM adaptor, followed by
library amplification of six PCR cycles and eluted in 30 μL
after post-amplification clean up. The library distribution
was analyzed by TapeStation 2200 (Agilent Technologies)
and quantified by Qubit (Life Technologies).
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NEBNext® Ultra ™ II DNA Library Prep
Library preparation was performed from MCC samples
(n = 2) with 5 ng and 20 ng input, breast tumor samples
(n = 4), and pre-cancerous breast lesions (papilloma) (n = 2)
with 5 ng DNA input as described in the NEBNext®
Ultra ™ II DNA Library Prep Kit (NEB E7645S/L,
New England BioLabs ® Inc.) with several minor mod-
ifications. In brief, DNA fragmented using the Covaris
S2 in 50 μL was used for NEBNext End Prep,
followed by an immediate adaptor ligation step with a
1.5 μM diluted adaptor. Clean-up of adaptor-ligated
DNA without size selection was carried out followed
by PCR amplification with eight cycles and ten cycles
for 20 ng and 5 ng input, respectively. After adding
resuspended AMPure XP Beads to the PCR products,
the mixture was incubated at room temperature for
at least 20 min instead of 5 min. Subsequently, after
adding 33 μL elution buffer (0.1 × TE) into the beads
after washing with ethanol, it was incubated for
10 min instead of 2 min. A total of 2 μL of the final
30 μL library was analyzed with the TapeStation for
the size distribution.
Low coverage whole genome sequencing
The libraries prepared by both KAPA Hyper and NEB-
Next kits were used for LC WGS. An Illumina Nextseq
platform (NextSeq 500) (paired-end 75 bp, on a mid-
output flow cell) was used to run the pooled, normalized
indexed libraries according to the standard protocol.
The final concentration was 2 nM pooled and diluted to
1.8 pM as the standard Illumina protocol. Sequencing of
those samples led to genome coverage of 1.6–1.8 × per
sample.
Molecular inversion probe SNP arrays
The Affymetrix Molecular Inversion Probe (MIP) 330 K
OncoScan array was used to analyze four breast cancer
samples (version 3) and two papilloma samples (version
2) and was performed according to the manufacturer’s
instructions by the Ramaciotti Centre for Genomics
(version 3, NSW, Australia) or Affymetrix Inc (version 2,
Santa Clara, CA, USA). DNA input was 40–100 ng for
this assay.
Data analysis
Reads were aligned with bwa mem (v0.7.12-r1039) [13]
to hg19 (GRCh37) after removal of sequencing primers
by cutadapt (v1.7.1) [14]. ControlFREEC (version 6.7)
[15] was used to estimate copy number from the low-
coverage WGS data in 50 kb windows across hg19, with
default parameters, no matched normal sample and
baseline ploidy set to 2. Down-sampling of bam files was
performed with samtools [16].
MIP data were pre-processed by the Ramaciotti Centre
for Genomics or Affymterix Inc., with tumor samples
batch normalized against Affymetrix controls [11].
All sample data were imported into Nexus (BioDiscov-
ery Inc., Hawthorne, CA, USA) and segmented using
SNP-FASST, a circular binary segmentation algorithm.
Copy number gains were called if the log2 ratio of the
segment was >0.15 and losses called if < –0.15. To re-
duce spurious calls, the genome was masked using a list
of published problematic regions, including highly re-
petitive centromeric regions, where DNA copy number
cannot be accurately measured [8].
Total CN profile overlap analysis was performed using
Partek Genome Suite (Partek Inc., St. Louis, MO, USA).
CNA segments for each matched pair were imported
and the “finding regions in multiple samples” tool run,
matching for event type (amplification/deletion). This
tool reports each CNA region shared at base-pair reso-
lution as well as each CNA region unique to a sample.
Shared CN neutral regions were calculated by subtract-
ing the length of all shared CNAs as well as sample only
CNA events from the total base pairs covered.
Median Absolute Pair-wise Difference (MAPD) score
was calculated as follows: if xi: is the log2 ratio for
marker i: then MAPD =median(|x i+1 − x i |,i ordered by
genomic position). This metric provides a measure of
the noise of the sample that is less dependent on true
biological copy number variation than, for example,
standard deviation.
FREEC normalized read counts in 50 kb bins were ex-
tracted from regions called as a gain or loss by FREEC
in at least one of the 5 ng, 20 ng, and 100 ng DNA in-
puts or the WGA libraries for MCT-4 and MCT-6 LC
WGS data. Gains or losses in regions lacking MIP array
probes and regions in the blacklist of Scheinin et al. [8]
were filtered out. The Pearson correlation of bin counts
in these CNA regions was calculated and used to cluster
by Euclidean distance using the hclust() function of R
3.2.1. Correlation between samples was visualized using
the pheatmap package.
Results
Comparing copy number alteration calls using low-input
DNA
We investigated a recently developed library preparation
method (NEBNext Ultra II) to reduce the required input
of DNA (Fig. 1). DNA was obtained from two archival
FFPE Merkel cell carcinoma (MCC) samples [6]. LC
WGS was performed on 100 ng, 20 ng, and 5 ng input
DNA. Compared with the standard 100 ng input, com-
parable CN profiles were observed using 5 ng or 20 ng
input DNA with 95 % of CN calls (gain, loss, or no
change) being concordant on average (Figs. 2 and 3). In
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addition, the quality control metric MAPD was compar-
able between the different DNA inputs (Fig. 3).
Since the low-input samples (both 20 ng and 5 ng)
were sequenced at a higher mean coverage (Table 1)
than the 100 ng input samples, the 20 ng and 5 ng sam-
ples were computationally down-sampled to simulate
the mean coverage of the 100 ng input (1.3×). The CN
profiles of the down-sampled low input samples still
showed 91–93 % concordance with CN profiles from the
matched 100 ng input samples (Fig. 3) with only minor
increases in MAPD (Fig. 3).
Comparison of CN profiles from low-input LC WGS and
MIP arrays
As the Affymetrix OncoScan MIP arrays are considered
by many to be a high-quality method for CN analysis of
FFPE samples [17], we compared the performance of
low-input LC WGS against these SNP arrays using
matched DNA from four FFPE breast cancer samples
(LPS1-LPS4). The CN profiles derived from LC WGS
were comparable to and, in some cases, improved upon
MIP arrays (Fig. 4). Overall, LC WGS with 5 ng of input
DNA resulted in CN profiles with >80 % (80–93 %) con-
cordance with those produced using 80–100 ng input
DNA on MIP arrays (Table 2). LC WGS typically covers
60–80 % of the sites in hg19 (Table 1), providing broader
sampling of the genome, apart from the genomic regions
known to be problematic for CN estimation [8], than
MIP arrays, which interrogate ~330,000 selected sites
that may not be distributed evenly across the genome.
It is noteworthy that from the overlap analysis (Fig. 3),
on average 15 % of the total CN profiles from LC WGS
and MIP differed; these differences fell into two categor-
ies. First, in some cases, LC WGS provided higher sensi-
tivity to detect small CN changes by providing more
even coverage across the genome than SNP arrays,
whereas, in other regions where SNP density was high,
the MIP arrays were able to detect CNA with length
<50 kb, below the detection limit imposed by the chosen
window size for LC WGS analysis. Second, many of the
large-scale differences were caused by segmentation and
thresholding differences, rather than true CN changes
(Additional file 1: Figure S1 and S2). For example, in LP
S1, MIP arrays called chromosome 4 as a loss whereas no
CNA was called from the LC WGS data (Additional file 1:
Figure S2). However, that particular loss could be ex-
plained by some segments sitting just below the threshold
in the MIP data whereas in LC WGS bins they did not,
due to normalization subtly shifting read counts upward
across the genome. For three samples, we had orthogonal
CN data from a targeted sequencing assay. Good concord-
ance was observed for CN variable regions between LC
WGS and this assay (LPS1 84 %, LPS2 94 %, and LPS4
61 % of CNA bp concordant). The concordance between
MIP arrays and the targeted assay was similar for CNA re-
gions (87 %, 95 %, and 61 %, respectively).
We also compared the performance of low-input LC
WGS against MIP arrays using matched DNA from two
FFPE pre-cancerous breast lesions in order to investigate
whether LC WGS could offer an improvement upon
very poorly performed MIP assays. Both low-quality
DNA LC WGS samples demonstrated improved reso-
lution of CNAs as compared with MIP arrays (Fig. 5). P1
showed markedly improved segmentation continuity,
Fig. 1 Experimental design testing a low-input method (NEBNext Ultra II) on copy number detection of two FFPE MCC samples by LC WGS as
well as the effect of WGA with or without NEB DNA repair treatment
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Fig. 2 Copy number profiles of MCC sample MCT4 with DNA input of (a) 100 ng, (b) 20 ng, and (c) 5 ng. Each point represents the normalized
read count ratio of a 50 kb sized bin. Separate chromosomes from 1 to 22 as well as X and Y are shown and a log2 (copy number/2) equal to
zero corresponds to a copy number of 2. Segments were removed from highly repetitive or problematic regions [8]
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with 1306 segments resolving into 68 segments. Sample
P2 showed a particularly big reduction in bin-to-bin
variability (Additional file 1: Figure S3) and the propor-
tion of data points greater than twice the mean CNA
value reduced from 17 % to just 1 %.
The FFPE repair treatment made little discernible dif-
ference to the appearance of the CN profiles (data not
shown) or MAPD scores (Fig. 3), although the sequen-
cing metrics were marginally improved compared with
untreated samples (Table 1).
Comparison of CN profiles between unamplified and
WGA samples with or without NEB FFPE repair treatment
We additionally evaluated WGA as an alternative
method of reducing the amount of native input DNA
into LC WGS without compromising CNA detection. In
parallel, we assessed whether a DNA repair procedure
(NEB Next) could improve LC WGS CNA detection
performance. The experimental strategy is summarized
in Fig. 1. Fifty nanograms of DNA derived from two
archival FFPE MCC samples [6] were subjected to WGA
and this yielded 2–4 μg of product, indicating that WGA
was successful. LC WGS was performed on the same
amount of input DNA (100 ng) from unamplified and
WGA samples. Compared with the unamplified samples,
the WGA samples had fewer reads mapped, approxi-
mately six times as many duplicate reads, and <15 % of
the genome covered by at least one read (Table 1). The
poorer sequencing metrics were reflected in the CN pro-
files with the unamplified samples showing less variabil-
ity in read counts per genomic segment and more
clearly discernible CNAs (Fig. 6). Further investigation
Fig. 3 a Concordance in CN profiles between samples, expressed as the percentage of sites in the genome called diploid, gain, or loss
concordant with 100 ng unamplified input of two MCC samples, MCT4, and MCT6. b Distribution of MAPD values from FREEC normalized bin
counts across all samples of low input 20 ng and 5 ng samples (blue) and low input 20 ng and 5 ng down-sampled to 1.3×, the mean depth of
the 100 ng input samples (purple). Whole genome amplified (WGA, red), Unamplified (UA, pink) along with NEB treated (NEB) or untreated (UT),
unamplified down-sampled to 0.2×, the mean depth of the WGA samples (purple) are also shown (all 100 ng input to library preparation)
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Mean coverage 1.34 0.14 1 0.18 1.96 2.23 1.53 0.19 1.24 0.22 2.25 2.13 2.66 1.68 1.8 2.1 1.98 0.75
Total reads (millions) 62.4 16.4 48.5 17.9 90.2 104.9 72.1 19.2 59.3 19.9 101.7 101.9 119.9 81.3 88.3
96.1 88.4 40.3
Mapped reads (millions) 61.7 14.0 47.0 15.4 88.5 102.5 71.2 15.9 57.7 17.1 101.1 100.9 119.0 80.8 87.7
95.5 87.7 39.5
Reads mapped (%) 98.96 85.57 96.97 85.85 98.04 97.66 98.73 83.18 97.35 86.17 99.4 99.1 99.28 99.39 99.29
99.32 99.23 98.09
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90.9 84.7 35.3
Target bases (%) > =
onefold coverage
58.26 9.17 48.53 11.41 67.97 71.54 61.91 11.45 56.48 14.2 74.44 72.15 80.14 62.94 65.31
73.84 72.33 33.37
Target bases (%) > =
tenfold coverage
0.14 0.01 0.07 0.01 0.48 0.78 0.19 0.01 0.11 0.02 0.6 0.52 0.83 0.26 0.3 0.31 0.25 0.06
Median fragment length 124 80 120 85 111 110 113 88 124 98 120 111 124 96 101 119 122 79
Tissue age (years) 5 5 5 5 5 5 5 5 5 5 5 5 2 7 2 9 7 11













revealed the poor sequencing results from the WGA
samples are mostly likely related to base calling and read
mapping being compromised by the presence of adap-
tors from WGA primers in the reads (Additional file 1:
Figure S4).
Overall, 77–87 % of the total CN profiles from matched
unamplified or WGA samples were concordant (Fig. 3).
Unsupervised clustering of MCT-4 and MCT-6 CNA
showed high intra-sample concordance with different in-
put amounts and methods, although the WGA data had
longer branch lengths (Additional file 1: Figure S5). Vari-
ance in read distribution as calculated by MAPD was
much higher in WGA samples (Fig. 3), consistent with the





Fig. 4 CN profiles for two breast tumor samples (LP S1 (a, b) and LP S4 (c, d)). a, c Low coverage WGS from 5 ng input of DNA. b, d MIP arrays
in the range of 80–100 ng input of DNA. Each data point in (a) and (c) represents normalized read count ratios from a 50 kb window. Segments
were removed from highly repetitive or problematic regions [8]
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Table 2 Concordance in CN profiles between samples, expressed as percentage of sites in the genome called diploid, gain, or loss
in both the LC WGS and MIP arrays for each breast tumor sample, and the percentage of sites called as gain or loss in the LC WGS
or MIP results only, respectively. Concordance in only CNV regions in both LC WGS and MIP arrays, expressed as percentage, for
each breast tumor sample
Sample Shared sites (%) WGS only sites (%) CNA WGS only (Mbp) MIP only sites (%) CNA MIP only (Mbp) Shared CNV (%)
LPS1 80.0 10.1 263 9.9 260 68
LPS2 83.4 7.7 202 8.8 231 74
LPS3 83.0 9.6 198 7.4 136 72





Fig. 5 CN profiles for two breast pre-cancerous samples (P1 (a, b) and P2 (c, d)). a, c MIP arrays in the range of 40–80 ng input of DNA. b, d LC
WGS from 5 ng input of DNA. Each data point in (b) and (d) represents normalized read count ratios from a 50 kb window. Segments were
removed from highly repetitive or problematic regions [8]
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Fig. 6 (See legend on next page.)
Kader et al. Genome Medicine  (2016) 8:121 Page 10 of 13
samples as compared with unamplified. Down-sampling
reads from the untreated unamplified samples to coverage
equivalent to the WGA samples (0.2×) revealed the reduc-
tion in consistent CNA calls from the latter could not be
attributed to differences in read depth alone (Fig. 3).
Discussion
Identifying CNAs by CGH or MIP arrays has been used
successfully for DNA derived from FFPE-fixed tissue, al-
though most often with a DNA input of >100 ng [4, 18,
19]. More recently, LC WGS has also been successfully
used to assess CNAs but again mostly using at least
100 ng of input DNA with coverage of 0.1–3× [6, 8, 9].
A very recent study used a complex cell-sorting and sin-
gle tube Ion Torrent amplicon-based library preparation
method to obtain LC WGS CN profiles from 126–300
cells without extracting DNA [8, 9, 20]. To open CN
analysis to samples with very limited DNA extracted by
standard methods and compatible with the common
Illumina sequencing platforms, we evaluated methods to
reduce the required DNA input for LC WGS.
A recently released library preparation method (NEB
Ultra II) adapted for very low input DNA was successfully
tested. The novel combination of this commercially avail-
able kit and our modifications for low input DNA enabled
us to obtain high-quality CN data, which was not previ-
ously possible. When we compared the CN profile and
MAPD results of 5 ng, 20 ng, and 100 ng input, we ob-
served almost negligible difference between these three in-
puts with 95 % overlap of CN profiles. Even down-
sampling of low input samples showed almost 92 % over-
lap of CN calls with the matched UA-UT 100 ng input,
which had lower mean coverage, without significantly
changing MAPD. This result confirmed that 5 ng of input
DNA produces total CN profiles that are highly concord-
ant with those obtained from 100 ng of input DNA at the
same depth of sequencing coverage. Interestingly, samples
we tested with even less than 5 ng input showed on aver-
age 90 % overlap of CN calls (data not shown), however,
at 2.5 ng and 1 ng inputs there were assay failures for
some samples, suggesting that a novel methodology needs
to be developed in future to robustly utilize DNA input
lower than 5 ng. We have subsequently tested an add-
itional 12 cases (21 DNA samples) and obtained good
quality CN data from all cases using 5 ng DNA (unpub-
lished data). Our tested cases are in the age range of 1–12
years and we found a weak trend between the age of the
block and the QC score calculated by Nexus (p = 0.06,
Kruskal–Wallis test for samples grouped in 5-year inter-
vals, Additional file 1: Figure S6). The difference in QC
score was subtle and did not affect detection of CNA.
We observed a high degree of similarity in CNAs de-
tected by low input LC WGS and MIP arrays, despite
the more than tenfold higher input DNA used for the
array-based method, with a much-improved CN profile
for samples that had performed poorly by MIP. Add-
itionally, the 15 % of total CN profile dissimilarity seen
on average between LC WGS and MIP arrays could be
explained by more uniform coverage of LC WGS or seg-
mentation and thresholding differences, rather than true
CN changes. A limitation of the study is the lack of
fresh-frozen tissue to extract high-quality DNA for com-
parison; however, high concordance of MIP array data
between FFPE and fresh-frozen derived DNA has been
demonstrated previously [4].
A limitation of the LC WGS approach is the inability
to determine allelic imbalance at high resolution due to
the low mean base coverage. However, in a high-quality
sample, increasing the average read depth to approxi-
mately tenfold would lead to >30 % of the genome hav-
ing sufficient coverage to call a genotype [21]. Even in a
low-quality FFPE-derived sample with reduced call rates,
this level would still be more than sufficient for detec-
tion of allelic imbalance and provide resolution similar
to MIP arrays. An FFPE WGS study of two breast cancer
samples identified ~2 million high-confidence SNP calls
from ~20-fold coverage [22].
One common method for increasing available input
DNA is WGA, which has been coupled with various
array-based systems for CNA studies [9, 23]. However,
in our study, WGA resulted in poor sequencing per-
formance (Table 1) and poor overlap (77–87 %) of CNA
data derived from unamplified DNA. While high con-
cordance rates and reproducibility has been reported
using WGA along with SNP genotyping [24], some pub-
lished studies have suggested that false-positive CNA
could be introduced randomly during the amplification
process and also that use of WGA could obscure true
CN changes [10, 23]. The high MAPD values from
WGA input and the noise seen in the CN profiles con-
curs with previous array-based studies [10].
While amplification bias during WGA may account
for some of our observations, the poor performance of
the WGA samples in our case also stems from the
(See figure on previous page.)
Fig. 6 CN profiles of unamplified (UA) and WGA samples. a CN profile of MCC sample MCT4, which is unamplified and untreated, with 100 ng
input of DNA. b CN profile of the same sample, which is unamplified and untreated, down-sampled to the similar coverage as the matched WGA
sample. c CN profile of the same sample, which is WGA and untreated. Each point represents the normalized read count ratio of a 50 kb sized
bin. Separate chromosomes from 1 to 22 as well as X and Y are shown and a log2 (copy number/2) equal to zero corresponds to a copy number
of 2. Segments were removed from highly repetitive or problematic regions [8]
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incorporation of universal adaptors prior to Illumina
library preparation, limiting nucleotide diversity during
the first bases of sequencing and resulting in a dramatic
decrease in the number and quality of sequenced frag-
ments (Additional file 1: Figure S4). Similar results were
reported previously [9]. Some of the technical challenges
presented by WGA may be overcome by optimization;
however, given that low input library preparation
methods give reliable and accurate results, the impera-
tive to use WGA is removed.
Interestingly, the FFPE DNA repairing method used did
not show any improvement in CN profile for either ampli-
fied or unamplified samples, although the sequencing
metrics were slightly better. One possible reason for
observing no significant differences in CN analysis using
the repair method is that while this method repairs single-
strand nicks, DNA fragmentation and DNA-protein cross-
links remain, likely leading to sub-optimal library prepar-
ation. This result suggested that such repair methods might
not be necessary for CN analysis; however, the possibility
remains that they could improve identification of other
genomic alterations such as somatic point mutations.
Conclusions
The major goal of this study was to investigate methods
for achieving accurate CN detection with as little input
DNA as possible. CNA are often associated with prognosis
for a variety of tumor types including pre-cancerous
lesions [1, 2, 25]. In situations where more than 10 ng
DNA is unavailable, either in research or clinical settings,
LC WGS using the low input method described here
would be a highly suitable method in terms of accuracy,
sensitivity, specificity, speed, and cost to detect CN
changes in FFPE samples. This technique opens up the
possibility of obtaining high-quality genome-wide copy
number from vast archives of FFPE tissue without depleting
the tissue resource, thereby enabling highly powered retro-
spective studies of associations of CN events with clinical
features. Small, previously intractable lesions can now be
investigated fully and, in addition, this technique could be
developed into a clinically feasible assay that, for the same
price as FISH, can interrogate the entire genome.
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